— Technology Description
Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
— Disease indication – SARS-CoV-2 infection (COVID-19)
Drug format
Drug class – Best-in-class
Research stage and Preliminary data – The inventors have developed and characterized these antibodies, creating a chimeric version with a human IgG backbone for SARS2-38. The antibodies have …
— Panel of 300 recombinant human monoclonal antibodies that are directed against influenza virus HA. These antibodies were derived from plasmablasts and germinal center B cells that were isolated from three healthy volunteers after influenza vaccination.
Turner, J. S., Zhou, J. Q., Han, J., Schmitz, …
— These are six monoclonal antibodies specific to SARS-CoV-2 Nucleocapsid protein that could potentially be used for COVID-19 diagnostics.
— Six recombinant human monoclonal antibodies that are directed against the conserved stalk region of influenza virus HA. This stalk region is currently being assessed as a potential candidate as a universal influenza vaccine. These antibodies can be used as diagnostics and also as validation tools fo…
— Species: Human
Target: SARS-CoV-2 nucleocapsid protein
Applications:
Description: Two recombinant fully human monoclonal antibodies that recognize SARS-CoV-2 spike protein (data below).
Related Web Links: Ellebedy Profile; Ellebedy Lab
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
